AVAV: 28% Slide, But Backlog Provides Floor – Wait for Proof Points

What happened

AVAV shares dropped 28.4% over three months as the market priced in margin compression from BlueHalo integration and a SCAR stop-work order that triggered a $151M goodwill impairment. Despite the decline, the company reported a $1.1B funded backlog and $2.1B in bookings, including a $186M Army Switchblade order and an ESAero deal to bolster long-term growth. However, the DeepValue Master Report highlights that only 39% of the backlog is expected to convert in fiscal 2026, with 61% slipping to FY2027 or later, and gross margins have collapsed to 24% from 38% a year ago. The SCAR program remains in limbo, with $1.49B in unexercised options now deemed unlikely to be awarded, compounding the visibility problem. While the backlog provides a floor, the stock at 93x EV/EBITDA leaves no room for error; the next 3-6 months must show funded backlog rising above $1.3B and gross margins recovering to 28%+ for the thesis to hold.

Implication

The 28% slide reflects real fundamental deterioration, not just market noise. The stock trades at 93x EV/EBITDA, pricing in a clean drone-at-scale conversion that filings contradict. Investors should wait for two concrete signs before accumulating: funded backlog must rise above $1.3B (from current ~$1.1B) and consolidated gross margins need to exit the 22-24% range toward 28%+. Until then, the risk of further guidance cuts or program delays outweighs the geopolitical tailwind narrative. A buy-in below $160 would offer a better margin of safety; above $220, consider trimming.

Thesis delta

The thesis remains a WAIT, but the recent 28% pullback narrows the downside to the $140 bear case and makes the $160 attractive entry more actionable. No structural change; the same proof points are required.